| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/31/2008 | WO2008091195A1 Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives |
| 07/31/2008 | WO2008090944A1 Spiro-ring compound |
| 07/31/2008 | WO2008090940A1 Pharmaceutical agent comprising dopamine d2-like receptor agonist as active ingredient and screening method |
| 07/31/2008 | WO2008090736A1 Pharmaceutical product for prevention and treatment of alzheimer's dementia |
| 07/31/2008 | WO2008090717A1 Adam inhibitor |
| 07/31/2008 | WO2008090678A1 Novel peptide |
| 07/31/2008 | WO2008090434A1 Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| 07/31/2008 | WO2008090429A1 Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| 07/31/2008 | WO2008090357A2 N, n; -substituted piperazines binding to melanocortin receptor |
| 07/31/2008 | WO2008090210A1 Methods for preventing and treating neurodegenerative disorders |
| 07/31/2008 | WO2008090209A2 Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders |
| 07/31/2008 | WO2008090117A1 Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| 07/31/2008 | WO2008090116A1 Novel pharmaceutical compositions |
| 07/31/2008 | WO2008090115A1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
| 07/31/2008 | WO2008090114A1 Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| 07/31/2008 | WO2008089961A1 Use of phosphatase inhibitors for the treatment of neurodegenerative diseases |
| 07/31/2008 | WO2008089659A1 The use of dopamine transporters and noradrenaline transporters dual inhibitors |
| 07/31/2008 | WO2008075978A3 An extract |
| 07/31/2008 | WO2008070529A3 A2a adenosine receptor antagonists |
| 07/31/2008 | WO2008070306A3 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators |
| 07/31/2008 | WO2008070306A2 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators |
| 07/31/2008 | WO2008069688A3 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| 07/31/2008 | WO2008068429A3 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression |
| 07/31/2008 | WO2008063232A3 Substituted pyrazolopyrimidines |
| 07/31/2008 | WO2008062424A3 Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators |
| 07/31/2008 | WO2008060448A3 Small molecule pak inhibitors |
| 07/31/2008 | WO2008052139A3 Ultra low dose doxepin and methods of using the same to treat sleep disorders |
| 07/31/2008 | WO2008051795A3 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative |
| 07/31/2008 | WO2008036653A3 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 07/31/2008 | WO2008013838A3 Pyridizinone derivatives |
| 07/31/2008 | WO2008005456A3 Fused heterocyclic inhibitors of d-amino acid oxidase |
| 07/31/2008 | WO2007141657B1 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| 07/31/2008 | WO2007141571A3 Aminothiazole derivatives as inhibitors of mark |
| 07/31/2008 | WO2007065036A3 Therapeutic conjugates and methods of using same |
| 07/31/2008 | WO2003064596A8 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 07/31/2008 | US20080184381 Schizophrenia-related voltage-gated ion channel gene and protein |
| 07/31/2008 | US20080183003 Neuroprotective agents; nitrate-functional, for example 1-amino-3,5-dimethyl-7-nitrateadamantane hydrochloride |
| 07/31/2008 | US20080182994 Crystallization from solvent; removal of impurities |
| 07/31/2008 | US20080182981 Method and medicament for inhibiting the expression of a given gene |
| 07/31/2008 | US20080182904 Antidepressants; psychological disorders |
| 07/31/2008 | US20080182891 Chromane and chromene derivatives and uses thereof |
| 07/31/2008 | US20080182889 Prodrugs of excitatory amino acids |
| 07/31/2008 | US20080182883 e.g. 1-Benzyl-3-pentyl-2-[6-(1H-tetraazol-5-ylmethoxy)-2-naphthyl]-1H-indole; stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 07/31/2008 | US20080182876 Histamine H3-Receptor Ligands and Their Therapeutic Application |
| 07/31/2008 | US20080182875 N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide |
| 07/31/2008 | US20080182860 Pyrimidine Compounds as Purine Receptor Antagonist |
| 07/31/2008 | US20080182859 Small organic molecule regulators of cell proliferation |
| 07/31/2008 | US20080182853 suppressing neuronal death; sudden loss of oxygen and/or energy loss, and degenerative diseases, such as Alzheimer's disease; Parkinson's disease; ischemic states |
| 07/31/2008 | US20080182848 anxiety; insomnia; high yielding; optically resolving eszopiclone using a multi-column continuous process or a simulated moving bed process; stationary phase used in chiral chromatography process is a derivative of tris(3,5-dimethylphenyl carbamate), or a derivative of tris- alpha -methylbenzylcarbamate |
| 07/31/2008 | US20080182846 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound |
| 07/31/2008 | US20080182831 e.g. Cyanomethyl (6 alpha ,11 beta ,16 alpha ,17 alpha )-17-({[(1,1-dimethylethyl)oxy]carbonyl}oxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylate; glucocorticoid receptor agonists of the androstane series; with other beta 2-adrenoreceptor agonist; asthma, rhinitis, eczema |
| 07/31/2008 | US20080182829 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens |
| 07/31/2008 | US20080182828 dominant estrogenic activity phase of three daily doses of an estrogen equivalent to 1 mg per day of 17 beta -estradiol per day and a dominant progestagenic activity phase of a combination of an estrogen and a progestogen equivalent to 90 mu g per day of norgestimate; hot flushes |
| 07/31/2008 | US20080182824 e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance |
| 07/31/2008 | US20080182819 Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders |
| 07/31/2008 | US20080182811 Activating a metabotropic glutamate receptor by administering one or more kinds of amino acids selected from amino acids other than glutamic acid; use in treating neurological diseases, cardiovascular diseases, surgical diseases, neurosurgical diseases, thoracic surgical diseases, orthopedic diseases |
| 07/31/2008 | US20080182803 extract from Cassia or Senna plants comprises rubrofusarin gentiobioside with egg white, egg membrane, milk whey, yeast/vegetable proteins, soy bean, L-cysteine, L-methionine, and vitamin C; synergistic; intracellular biosynthesis of glutathione stimulator; liver, brain, vision, or immune disorders |
| 07/31/2008 | US20080182800 Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides |
| 07/31/2008 | US20080182787 Protein isolated from plants (Moringa) or synthesized by recombinant DNA technology; enzyme inhibitors; prevention and treatment of metabolic, cardiovascular, and inflammatory diseases |
| 07/31/2008 | US20080182784 Reduction or mutation in kalirin indicates senile dementia related to diabetes; Alzheimer's disease; inhibiting nitric oxide cytotoxicity |
| 07/31/2008 | US20080182775 Administering analogs of luteinizing hormone-releasing hormone, leuprolide; inhibits testosterone secretion |
| 07/31/2008 | US20080182314 Neuronal serine threonine protein kinase |
| 07/31/2008 | US20080182313 Polypeptide of 250-419 contiguous amino acids of SEQ ID NO:1, where tyrosine 216 is phosphorylated and the polypeptide will crystallize; biological activity consisting of binding a GSK3 inhibitor and kinase activity; antidiabetic agents; Alzeimer's disease; antiinflammation agents; biological screening |
| 07/31/2008 | US20080182294 Recombinant clostridial neurotoxins (botulinum) having functional binding, translocation, and therapeutic domains; also an amino acid sequence susceptible to specific cleavage by proteases in vitro following expression as a single chain; inserts; therapeutic agents, transporter molecules; drug delivery |
| 07/31/2008 | US20080182292 Investigation of new membrane tubes containing F-actin and myosin of a diameter of 50-400 nm and <50+ micrometers length which span the cells; spreading, incubating and staining with a detectable microscopic stain, fluorescent dye, to obtain stained plasma membranes for 3-D cell microscopy |
| 07/31/2008 | US20080182266 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 07/31/2008 | US20080181966 Modafinil pharmaceutical compositions |
| 07/31/2008 | US20080181954 Genetically altered chondrocyte expresses a therapeutic agent; implanting a biocompatible substrate into a target region; brain, heart, liver, kidney, intestinal tract, spleen, smooth and skeletal muscles, eye, ganglions, lungs, gonads, pancreas |
| 07/31/2008 | US20080181942 inter alia, treating and/or preventing symptoms; Spasticity |
| 07/31/2008 | US20080181937 Vitamin C, Vitamin E, DHA and Curcumin; treating an individual who is at increased risk of developing Alzheimer's disease because of family history |
| 07/31/2008 | US20080181902 Mutant protofibril for active immunisation; synuclein genes, proteins; Parkinson's disease; dementia |
| 07/31/2008 | US20080181901 Protein modulator of the plasma membrane Na,K-ATPase |
| 07/31/2008 | US20080181883 Purified Antigen for Alzheimer's Disease and Methods of Obtaining and Using Same |
| 07/31/2008 | US20080181882 treating a neuropsychiatric disorder with siRNA, polyamides, antisense RNA, synthetic peptide nucleic acids, antibody, Fab fragment; enhancing tyrosine phosphorylation; long lasting treatment, inhibit side effects; biodrugs; gene therapy; drug screening |
| 07/31/2008 | US20080181876 phosphodiesterase (PDE3,4,10,11) inhibitor (Ibudilast, Rolipram, Doxofylline, Roflumilast, Dipyridamole, Cilostazol, Theophylline, Propentofylline) or glial attenuator (Minocycline, interleukin receptor antagonist, MAP-kinase inhibitor) in combination with opioids (Morphine and Oxycodone) |
| 07/31/2008 | US20080181873 produce more stem cells in vivo or in vitro by culture, for transplantation into patient; increase neurogenesis or new olfactory neuron numbers; stroke, neurodegenerative disease of Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease |
| 07/31/2008 | US20080181872 adeno-associated virus vector biodrug for Parkinson's disease, Huntington's disease, Alzheimer's disease, Down syndrome, rheumatoid arthritis, Crohn's disease; gene therapy of amyotrophic lateral sclerosis; drug creening; sustained release for prevent oxidative damage from superoxide buildup |
| 07/31/2008 | US20080181865 Methods of treating neurological conditions with hematopoeitic growth factors |
| 07/31/2008 | DE102004039196B4 Neue Formulierung für L-Tryptophan New formulation of L-tryptophan |
| 07/31/2008 | CA2676620A1 Methods for preventing and treating neurodegenerative disorders |
| 07/31/2008 | CA2676357A1 Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| 07/31/2008 | CA2676214A1 Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives |
| 07/31/2008 | CA2676175A1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
| 07/31/2008 | CA2676172A1 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl-) |
| 07/30/2008 | EP1950302A2 Streptococcus antigens |
| 07/30/2008 | EP1950224A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950223A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950211A1 Process for production of cinnamamide derivative |
| 07/30/2008 | EP1949936A2 Controlled release composition and method of producing the same |
| 07/30/2008 | EP1949906A1 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 07/30/2008 | EP1949904A2 Cell therapy for chronic stroke |
| 07/30/2008 | EP1948689A1 High activity growth factor mutants |
| 07/30/2008 | EP1948667A2 Thiazolo[4,5-c]pyridine derivatives as mglu5 receptor antagonists |
| 07/30/2008 | EP1948665A2 Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists |
| 07/30/2008 | EP1948662A2 Tricyclic compounds useful as oxytocin receptor agonists |
| 07/30/2008 | EP1948661A1 Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors |
| 07/30/2008 | EP1948657A1 Azaindazoles useful as inhibitors of kinases |
| 07/30/2008 | EP1948653A1 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 07/30/2008 | EP1948648A2 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
| 07/30/2008 | EP1948646A2 Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |